

Immunology of Hodgkin Lymphoma

Guest Editor:

Dr. Arjan Diepstra

Department of Pathology and
Medical Biology, University of
Groningen, University Medical
Centre Groningen, 9700 RB
Groningen, The Netherlands

Deadline for manuscript
submissions:

closed (31 January 2023)


Message from the Guest Editor

Dear Colleagues,

Hodgkin Lymphoma (HL) is a cancer of lymph nodes and is commonly diagnosed in adolescents and young adults. It is characterized by a minority of tumor cells, called Hodgkin and Reed–Sternberg (HRS) cells, that are surrounded by a large number of reactive immune cells. The HRS cells originate from germinal center B-cells and are highly aberrant. It is hard to understand how they can develop within lymph nodes, especially in young and otherwise healthy individuals. This is even more apparent in cases in which the immunogenic Epstein–Barr-virus (EBV) is present in the tumor cells. Not only do (precursor) HRS cells escape from a multitude of anti-tumor immune responses, they even shape and hijack the tumor microenvironment (TME) for their own benefit. This may explain why novel treatments like immune checkpoint inhibitors that target the TME are highly effective in HL.

You are invited to contribute original research to this Issue on the Immunology of HL. The main theme is the cross-talk between (cells of) the TME and (precursor) HRS cells. Manuscripts on immunology related blood biomarkers and genetic susceptibility are also invited.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)